Navigation Links
Lilly announces Tapiero retiring; Zulueta promoted to senior vice president and president of Emerging Markets
Date:10/24/2013

INDIANAPOLIS, Oct. 24, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Alfonso "Chito" Zulueta will be promoted to senior vice president and president of the Emerging Markets business effective Jan. 1, 2014. Zulueta will replace Jacques Tapiero who will retire Jan. 31, 2014, after 31 years of service to the company.

Zulueta has been president and general manager of Lilly Japan since 2008. In his new role, he will lead the company's efforts in many of the world's fastest-growing markets in Asia, Latin America, Middle East and Africa, plus Russia and Turkey.  Zulueta will report to John Lechleiter, Ph.D., chairman, president, and CEO, and will serve on the company's executive committee.

Tapiero joined Lilly in 1983 as a financial analyst. He became president of Emerging Markets in 2009. Prior to that, he had served as president of the intercontinental region for Lilly, which comprised offices in Asia, Australia, Africa, the Middle East, Canada, Latin America, and Russia, and had been general manager of several affiliates.

"Jacques Tapiero has made extraordinary contributions to our company throughout his 31-year career with Lilly, culminating in 2009 with his appointment to lead our important Emerging Markets business," Lechleiter said. "Jacques' leadership has been characterized by strong operational skills and a keen focus on the development of Lilly people around th
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lilly Reports Third-Quarter 2013 Results
2. FDA Grants Lillys Ramucirumab Priority Review as a Potential Single-Agent Treatment for Advanced Gastric Cancer
3. Lilly Declares Fourth-Quarter 2013 Dividend
4. Lilly Reintegration Scholarship Applications Available for 2014-2015 Academic Year
5. Lilly to host investment community meeting at its Indianapolis headquarters on Thursday, October 3, 2013
6. Data Presented at 49th EASD Annual Meeting Show Treatment with Lillys Investigational Dulaglutide Resulted in Improved Patient-Reported Health Outcomes
7. Lilly Announces Second Positive Ramucirumab Phase III Gastric Cancer Study Meets Primary Endpoint; Phase III Lilly/TRIO Breast Cancer Study Misses Primary Endpoint
8. Exosome Diagnostics Enters Collaboration Agreement with Lilly for Exosome Blood-Based Biomarker Discovery
9. Lilly to Present Data Across its Diabetes Portfolio at the 49th European Association for the Study of Diabetes Annual Meeting
10. Humana and Lilly Form Research Collaboration to Improve Health Care Outcomes
11. Dr. Marschall S. Runge Elected to Lilly Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... York , September 22, 2014 ... (MRI) market has been recently added to Transparency Market ... (MRI) Market: Global Market Analysis, Size, Share & Forecast ... MRI market, which valued US$ 3.9 billion in 2011, ... 2011 to 2017(the forecast period of the report), and ...
(Date:9/22/2014)... 2014  Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical ... today announced it has completed three phase 3 ... Obiltoxaximab is an anti-toxin in development for the ... studies support the safety and tolerability of the ... therapeutic dose. The conclusion of these studies marks ...
(Date:9/22/2014)... -- Persistence Market Research ( http://www.persistencemarketresearch.com/ ) ... Ophthalmic Devices: Asia to Witness ... at USD 29,171.5 million in 2014 and is expected ... to 2020, to reach an estimated value of USD ... Market Study on Ophthalmic Devices:  Asia  to ...
Breaking Medicine Technology:Global Magnetic Resonance Imaging (MRI) Market Worth US $4.8 Billion by 2017: Transparency Market Research 2Global Magnetic Resonance Imaging (MRI) Market Worth US $4.8 Billion by 2017: Transparency Market Research 3Global Magnetic Resonance Imaging (MRI) Market Worth US $4.8 Billion by 2017: Transparency Market Research 4Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 2Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 4Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 5Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 6Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 2Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 3Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 4Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 5
(Date:9/22/2014)... MONDAY, Sept. 22, 2014 (HealthDay News) -- Metformin, a ... risk of low levels of thyroid-stimulating hormone (TSH) among ... The researchers cautioned that low TSH levels may ... a cause-and-effect link was not established in this study. ... thyroid (hypothyroidism), there were 495 incidences of low levels ...
(Date:9/22/2014)... The “ Ztylus ” was featured on NewsWatch ... reviews and features the latest technology gadgets and services available ... expert, conducted the review and shared with viewers how it’s ... gives users four lens options for their camera. , The ... Tech Report, which reviews and features the latest technology gadgets ...
(Date:9/22/2014)... 2014 “The Race is On!” for the ... Sunday, October 12, 2014 as it moves to its new ... As the signature fundraising and awareness event for Susan G. ... Phoenix Race for the Cure provides supporters of all ages ... and even sleeping in. , “Moving the Race to ...
(Date:9/22/2014)... perspiration these symptoms are a few of the ... heart rate and plays a crucial role in its ... Aviv University points to an additional complication caused by ... Mammalian Genome , was conducted by Prof. Karen ... of Human Molecular Genetics and Biochemistry at TAU,s Sackler ...
(Date:9/22/2014)... A study led by University of North Carolina at ... the accurate diagnosis of people who are experiencing the ... delusions that define the development of severe mental disorders ... early adulthood and affects about 1 in every 100 ... person can be a life compromised, and the burden ...
Breaking Medicine News(10 mins):Health News:Diabetes Drug Metformin May Affect Thyroid in Some Patients 2Health News:NewsWatch Recently Featured the Phone Case “Ztylus” on National Television 2Health News:22nd Annual Susan G. Komen Phoenix Race for the Cure® 2014 Moves to Downtown Phoenix 2Health News:22nd Annual Susan G. Komen Phoenix Race for the Cure® 2014 Moves to Downtown Phoenix 3Health News:Lack of thyroid hormone blocks hearing development 2Health News:Blood test may help determine who is at risk for psychosis 2
... HOUSTON - A vaccine that turns the immune system ... drives the most aggressive form of glioblastoma multiforme improved ... researchers at Duke University and The University of Texas ... Journal of Clinical Oncology . Eighteen newly diagnosed ...
... Oct. 6, 2010 A set of proteins found in ... to diagnose Alzheimer,s disease, researchers at UT Southwestern Medical Center ... An analysis of the proteins, plus a clinical exam, proved ... accurate in ruling it out in people without the disease, ...
... Reinberg HealthDay Reporter , TUESDAY, Oct. 5 (HealthDay ... young adults admit they are binge drinkers, health officials said ... as having four or more drinks for women, and five ... -- numbers that are different because men and women metabolize ...
... to a discovery by a Saint Louis University researcher, scientists ... better control cholesterol levels in blood. Led by ... at Saint Louis University and published in a recent issue ... of the United States of America, the study found that ...
... New neuroscience research by life scientists from UCLA and Australia may ... to brain injury or disease. By examining how ... way the brain first captures and encodes a situation or event ... The study is published in the Sept. 29 edition ...
... By Randy Dotinga HealthDay Reporter , ... study is the latest to suggest that testosterone may ... causing serious side effects. Researchers aren,t yet ready ... to female patients. However, the treatment does hold some ...
Cached Medicine News:Health News:Vaccine extends glioblastoma patients' survival in phase II trial 2Health News:Blood test could diagnose Alzheimer's disease, UT Southwestern researchers find 2Health News:1 in 4 U.S. Teens and Young Adults Binge Drink: CDC 2Health News:1 in 4 U.S. Teens and Young Adults Binge Drink: CDC 3Health News:Better cholesterol drugs may follow Saint Louis University researcher's breakthrough 2Health News:Neuroscience research may help patients recover from brain injury 2Health News:Testosterone Could Boost Health of Heart Failure Patients 2
... a range of Milli-Q ultrapure water ... quality requirements. Each of the five ... specifically target contaminants detrimental to particular ... and ICP-MS. The systems incorporate a ...
... Millipore has developed a range ... to match specific water quality requirements. ... systems is designed to specifically target ... as HPLC, molecular biology and ICP-MS. ...
... range of Milli-Q ultrapure water systems ... requirements. Each of the five new ... target contaminants detrimental to particular applications ... ICP-MS. The systems incorporate a high ...
... has developed a range of Milli-Q ... specific water quality requirements. Each of ... designed to specifically target contaminants detrimental ... molecular biology and ICP-MS. The systems ...
Medicine Products: